Familial Amyloid Neuropathies (Metabolic Disorder) – Drugs in Development, 2021

Global Markets Direct’s, ‘Familial Amyloid Neuropathies – Drugs In Development, 2021’, provides an overview of the Familial Amyloid Neuropathies pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies

– The report reviews pipeline therapeutics for Familial Amyloid Neuropathies by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Familial Amyloid Neuropathies therapeutics and enlists all their major and minor projects

– The report assesses Familial Amyloid Neuropathies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Neuropathies

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ADRx Inc

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

BSIM Therapeutics SA

Corino Therapeutics Inc

Novo Nordisk AS

Precision Biosciences Inc

Proclara Biosciences Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Familial Amyloid Neuropathies - Overview

Familial Amyloid Neuropathies - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Familial Amyloid Neuropathies - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Amyloid Neuropathies - Companies Involved in Therapeutics Development

Familial Amyloid Neuropathies - Drug Profiles

Familial Amyloid Neuropathies - Dormant Projects

Familial Amyloid Neuropathies - Discontinued Products

Familial Amyloid Neuropathies - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Familial Amyloid Neuropathies, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Familial Amyloid Neuropathies – Pipeline by ADRx Inc, 2021

Familial Amyloid Neuropathies – Pipeline by Akcea Therapeutics Inc, 2021

Familial Amyloid Neuropathies – Pipeline by Alnylam Pharmaceuticals Inc, 2021

Familial Amyloid Neuropathies – Pipeline by BSIM Therapeutics SA, 2021

Familial Amyloid Neuropathies – Pipeline by Corino Therapeutics Inc, 2021

Familial Amyloid Neuropathies – Pipeline by Novo Nordisk AS, 2021

Familial Amyloid Neuropathies – Pipeline by Precision Biosciences Inc, 2021

Familial Amyloid Neuropathies – Pipeline by Proclara Biosciences Inc, 2021

Familial Amyloid Neuropathies – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Familial Amyloid Neuropathies – Dormant Projects, 2021

Familial Amyloid Neuropathies – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Familial Amyloid Neuropathies, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports